Cancer Drug Prescriptions Soar Amidst Misinformation

In the months following a notable episode, prescriptions for ivermectin and fenbendazole experienced a substantial increase, with cancer patients showing a more than doubled rate of prescriptions during early 2025 compared to the previous year. This rise is primarily observed among men, white patients, and those in the southern United States, according to research. Oncologists are expressing concern that patients might opt for these unproven treatments over conventional therapies, potentially delaying or abandoning effective care. The findings underscore the pervasive influence of easily accessible health information, both accurate and inaccurate, from social media, podcasts, and AI-powered chatbots. Cancer patients are particularly vulnerable due to the intense fear, urgency, and uncertainty they face, making them susceptible to anecdotal evidence and promises of 'magic cures.' While the overall prescription rate for these drugs remains low, their rapid increase has alarmed medical professionals. Experts emphasize that while ivermectin has FDA approval for other conditions and some preclinical studies suggest anticancer potential, anecdotal patient stories are not scientific proof. Medications that show promise in early research often fail in human trials. Doctors warn that high doses could be toxic and interfere with conventional treatments. Some patients have reportedly chosen ivermectin despite medical advice, returning months later with worsened cancer conditions.